Table 3.
Treatment-emergent adverse events reported during the study.
Oxybutynin 100 mg (n = 8) |
||
---|---|---|
Event n | Subject n (%) | |
All events | 11 | 5 (62.5) |
Eye disorders | ||
Blurry vision | 1 | 1 (12.5) |
Gastrointestinal disorders | ||
Dry mouth | 1 | 1 (12.5) |
Lip dry | 1 | 1 (12.5) |
Nausea | 1 | 1 (12.5) |
General and administration conditions | ||
Fatigue | 2 | 2 (25.0) |
Feeling hot | 1 | 1 (12.5) |
Nervous system disorders (headache) | 4 | 3 (37.5) |